An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

NCT01511393 · readout ≤ 4,882 d

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →. With AstraZeneca, Eli Lilly and Company, United BioSource, LLC.

Phase

—

Status

Enrolling by invitation

Study type

Observational

Enrollment

6,750estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

Jan 2012

not stated

When the study began enrolling

Primary completion

Dec 2039

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2039

estimated

The whole study's end, after follow-up

First posted

2012-01-18

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2023-06-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Diabetes
Diabetes Mellitus, Type 2
Medullary Thyroid Carcinoma
Weight Management

Intervention

Other: No treatment given

Primary outcome

what the primary-completion date above is the date OF

Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.

measured Up to 15 years

Publications

PMID 33179845 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed